Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Has Consensus Target Price of $37.00 According to Brokerages

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $37.00.

A number of research analysts recently issued reports on LKFT shares. UBS Group raised shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research note on Wednesday, September 23rd. Morgan Stanley decreased their target price on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 11th. Royal Bank Of Canada upgraded Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. Weiss Ratings lowered Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, September 16th. Finally, TD Cowen initiated coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, August 21st. They set a “buy” rating on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ABC Arbitrage SA acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at about $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth approximately $248,000. QRG Capital Management Inc. raised its stake in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares during the period. Finally, Madison Avenue Partners LP boosted its holdings in Lakefront Biotherapeutics American Depositary Shares by 0.8% in the fourth quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after acquiring an additional 17,394 shares in the last quarter. 32.46% of the stock is owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Price Performance

LKFT stock opened at $29.37 on Wednesday. Lakefront Biotherapeutics American Depositary Shares has a fifty-two week low of $25.68 and a fifty-two week high of $37.78. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -20.83 and a beta of 0.24. The business’s fifty day moving average price is $28.32 and its two-hundred day moving average price is $28.75.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.00. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. Research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.27 EPS for the current year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.